Full Press Release Details
Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II.
IMMP
Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II
Key Takeaway: Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II
Price reaction · baseline $2.18 (2024-12-13 close) · 1 other IMMP headline(s) in the window, move may be shared
day 0 close · peak
-4.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)